Monica E. Loghin

Neurology

1515 Holcombe Blvd
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial.

Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial.

Journal: Neuro-oncology advances

Published: June 24, 2025

Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses : Treatment intensification, margin reduction and epigenetic stratified outcomes with radiation therapy and chemotherapy.

Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses : Treatment intensification, margin reduction and epigenetic stratified outcomes with radiation therapy and chemotherapy.

Journal: Journal of neuro-oncology

Published: May 05, 2025

Extra-central nervous system metastasis from high-grade glioma: a single-institution experience.

Extra-central nervous system metastasis from high-grade glioma: a single-institution experience.

Journal: Journal of neuro-oncology

Published: January 09, 2025

Early Outcomes from Proton Craniospinal Irradiation for Leptomeningeal Metastasis From Solid Tumors.

Early Outcomes from Proton Craniospinal Irradiation for Leptomeningeal Metastasis From Solid Tumors.

Journal: Advances in radiation oncology

Published: August 01, 2024

Accelerated tumor progression after COVID-19 infection in patients with glioblastoma: A retrospective case-control study.

Accelerated tumor progression after COVID-19 infection in patients with glioblastoma: A retrospective case-control study.

Journal: Neuro-oncology practice

Published: July 15, 2024

Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.

Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.

Journal: Nature communications

Published: July 04, 2024

Toxicity in the era of immune checkpoint inhibitor therapy.

Toxicity in the era of immune checkpoint inhibitor therapy.

Journal: Frontiers in immunology

Published: June 10, 2024

Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial.

Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial.

Journal: Nature communications

Published: February 14, 2024

Patterns of failure after radiation therapy in primary spinal high-grade gliomas: A single institutional analysis.

Patterns of failure after radiation therapy in primary spinal high-grade gliomas: A single institutional analysis.

Journal: Neuro-oncology advances

Published: September 21, 2022

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.

Journal: Nature communications

Published: April 08, 2021

Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.

Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.

Journal: Neuro-oncology

Published: November 23, 2019

Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.

Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.

Journal: Cancer

Published: May 30, 2018

Showing 1-12 of 22

Last Updated: 09/26/2026